Deutsche Bank
TRDA icon

Deutsche Bank’s Entrada Therapeutics TRDA Stock Holding History

Deutsche Bank’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$147K Sell
23,181
-3,375
-13% -$23.4K ﹤0.01% 3241
2026
Q2 		$195K Buy
26,556
+1,877
+8% +$18K ﹤0.01% 3268
2026
Q1 		$311K Buy
24,679
+3,858
+19% +$44.2K ﹤0.01% 2812
2025
Q4 		$214K Sell
20,821
-187
-0.9% -$1.58K ﹤0.01% 2982
2025
Q3 		$122K Buy
21,008
+5,473
+35% +$32K ﹤0.01% 3271
2025
Q2 		$104K Sell
15,535
-3,969
-20% -$31.9K ﹤0.01% 3236
2025
Q1 		$176K Sell
19,504
-2,236
-10% -$27.9K ﹤0.01% 3012
2024
Q4 		$376K Buy
21,740
+7,757
+55% +$141K ﹤0.01% 2771
2024
Q3 		$223K Buy
13,983
+3,756
+37% +$59.2K ﹤0.01% 2881
2024
Q2 		$146K Buy
10,227
+118
+1% +$1.68K ﹤0.01% 2976
2024
Q1 		$143K Buy
10,109
+301
+3% +$4.26K ﹤0.01% 3006
2023
Q4 		$148K Sell
9,808
-230
-2% -$3.41K ﹤0.01% 3031
2023
Q3 		$159K Buy
10,038
+1,532
+18% +$24.1K ﹤0.01% 2923
2023
Q2 		$129K Buy
+8,506
New +$117K ﹤0.01% 3139
2022
Q2 		– Sell
-4,959
Closed -$47K – 4323
2022
Q1 		$47K Sell
4,959
-608
-11% -$6.52K ﹤0.01% 3864
2021
Q4 		$95K Buy
+5,567
New +$135K ﹤0.01% 3733

Other funds holding TRDA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Deutsche Bank's TRDA Position: Q3 2026 in Review

Deutsche Bank reduced its Entrada Therapeutics (TRDA) stake by 13% in Q3 2026, selling an estimated $23.4K and leaving 23,181 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

Deutsche Bank first reported a position in TRDA in Q4 2021 and has held it in 16 quarters since. The position peaked at $376K in Q4 2024. 76 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Deutsche Bank held 23,181 shares of Entrada Therapeutics worth $147K as of Q3 2026.
  • Deutsche Bank sold 3,375 Entrada Therapeutics shares in Q3 2026, an estimated $23.4K.
  • Entrada Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3241 holding.
  • Deutsche Bank first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Deutsche Bank's Entrada Therapeutics position peaked at $376K in Q4 2024.
  • 76 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.